Incorporating MM Polarization in hybrid QM/MM calculations

Lead Research Organisation: University of Essex
Department Name: Biological Sciences

Abstract

Computer simulation now plays a major role in understanding biological systems and in the design of molecules as new materials and new pharmaceuticals. In cases where it is important to study the molecules in atomic-level detail so that the distribution of electrons within the molecules can be understood, then quantum mechanics is the method of choice. In cases where the environment surrounding these molecules affects this distribution of electrons, then hybrid quantum mechanical / molecular mechanics (QM/MM) methods are used. The QM means that the molecule of interest can be studied accurately; the MM means that the environment that this molecule is in can also be taken into account, albeit at a lower level of accuracy. Within the MM part of these calculations, it is assumed that the electrons have a fixed distribution that does not change in response to the QM region of interest. Here we propose to introduce new computer methods so that the polarization of the electron distribution within the MM region can be taken into account. A simple illustration should highlight the importance of this effect. When a drug binds to an enzyme, the structure of both the drug and the enzyme must flex to accommodate each other. A similar accommodation is occurring in the spatial distribution of the electrons. Ignoring this redistribution (i.e. polarization) is therefore rather like attempting to put on a glove that is almost frozen solid. A significant part of the project will involve work to ensure that these methods can be readily used by other scientists. Applications of this new method will enable increased atomic and molecular level understanding of biological processes. The scientists that will benefit will not only include theoreticians but also enzymologists, those involved in drug design, bioinorganic chemists, photochemists, material scientists, plant scientists, spectroscopists, and those involved in biotechnology software companies.

Technical Summary

Hybrid quantum mechanical / molecular mechanics (QM/MM) methods have now developed into powerful research tools for analysing mechanisms of both inorganic processes and enzymes. Because of the underlying quantum mechanical (QM) treatment of the region of interest, they provide the main approach to studying bond rearrangements in proteins. Advances in quantum chemistry mean that these calculations can now be carried out with reasonable accuracy. The molecular mechanics (MM) treatment of the environment ensures realistic calculations. Usually in QM/MM, the QM entity is polarized by the MM entity but the MM entity is not polarized. This asymmetry is vaguely acceptable because the focus is on the QM region. Nevertheless, there is evidence to suggest that MM polarization can be important and so here we propose to implement MM polarization into QM/MM. Here we propose to do this using induced charges, for several reasons. Firstly, they are easy to implement (so any advantages gained can be implemented in additional computer codes), secondly they are based on the electrostatic potential and so are fully consistent with the derivation of many modern force fields. Thirdly, the polarization energy determined is readily compatible with that arising from polarization of the wave function. Fourthly, the computational cost of MM polarization via induced charges is low. Optimal strategies for the efficient use of the methods will be determined. A significant part of the project will involve work to ensure that these methods can be readily used by other scientists. Applications of this new method will enable increased atomic and molecular level understanding of biological processes such as characterisation of transition states and calculation of kinetic isotope effects, understanding transition state stabilization, biological electron transfer, protein-ligand interactions, design of anti-cancer drugs and sequence specific DNA binding ligands.
 
Description The search for a new drug may start on the computer by 'docking' potential molecules into a structure of the drug target, which is typically an enzyme or a receptor. Molecules that are calculated to fit well can therefore be made and tested experimentally, while those calculated to have a poor fit can be ignored, thus saving time and expense. However, these calculations do not always work well. These calculations usually assumes that the atomic charge distribution on the molecule and the enzyme does not change when the molecule approaches the enzyme even when the charges on some of the atoms are quite high and might therefore affect each other, i.e. one molecule might polarize the other. We have developed a method of including enzyme polarization and ligand polarization in docking that can be combined with standard state-of-the art docking software. This should greatly reduce one of the main errors in docking. Inclusion of polarization by this method typically halves the proportion of compounds incorrectly docked using GLIDE, a state-of the art docking program and therefore has the potential to facilitate the drug design process.
Exploitation Route It has since been proposed that water molecules play a far bigger role in drug design than was previously envisaged, as a drug will benefit energetically from displacing an 'unhappy' water molecule (i.e. one that binds weakly to the protein), but will not benefit from displacing a 'happy' water molecule. Jon Mason, Heptares, is one of the main proponents (as judged by frequency of conference talks) of the importance of this effect in drug design. Certainly, we observe greater improvement from our methods when appropriate water molecules are included, but the key question is which water molecules to include. The natural extension to our work is to investigate the energetics of water placement within protein active sites by including polarization, so that more accurate inclusion of 'happy' water molecules can be used to give improved docking results. At one level this is trivial, but we have opened discussions with Dr Mason (and also with Schrodinger who produce relevant software) to test these ideas on public domain structures that are nevertheless pharmaceutically important and where the subtleties of ligand binding are well-understood. Collaboration with Schrodinger or pharma is likely to ensure that the methods are well-focused to have the maximum impact.
Sectors Agriculture, Food and Drink,Chemicals,Digital/Communication/Information Technologies (including Software),Pharmaceuticals and Medical Biotechnology

URL http://ftp://ftp.essex.ac.uk/pub/oyster
 
Description Industry interchange programme
Amount £50,210 (GBP)
Organisation Biotechnology and Biological Sciences Research Council (BBSRC) 
Sector Public
Country United Kingdom
Start 10/2010 
End 06/2011
 
Description Project Grant
Amount £175,421 (GBP)
Funding ID PG/12/59/29795 
Organisation British Heart Foundation (BHF) 
Sector Charity/Non Profit
Country United Kingdom
Start 03/2014 
End 02/2017
 
Description Research Leader Fellowship / Industry Interchange
Amount £98,509 (GBP)
Funding ID G1001812 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 10/2011 
End 09/2014
 
Description CGRP antagonists 
Organisation Aston University
Country United Kingdom 
Sector Academic/University 
PI Contribution Modelling interactions of ligands with the CGRP receptor and other proteins.
Collaborator Contribution Pharmonovo supply ligands and coordinate the project David Kendall, PhD, Professor of Pharmacology, University of Nottingham; in vitro investigations of receptor activity and behavioural evaluation of novel compounds in animal models. Over 30 years of experience of GPCR pharmacology. OnTarget Chemistry. Fredrik Lehmann: synthetic chemistry University of Reading. Graeme Cottrell, PhD, Lecturer in Cellular and Molecular Neuroscience; In vitro investigations of the effects of novel compounds on CGRP trafficking and signalling; Over 10 year experience in GPCR trafficking and signalling University of Aston. David Poyner, PhD, Professor of Pharmacology. Mapping antagonist binding sites on the CGRP receptor. 25 year experience of studying the CGRP receptor. University of Essex, Mike Hough, X-ray crystallography Kings College, London. Susan Brain, PhD, Professor of Pharmacology, Vascular Biology and Inflammation. In vivo measurements of blood flow in murine models, especially in first pre-clinical experiments to determine potency, mode of administration and duration of action. PharmInVivo. Zsuzsanna Helyes, MD, PhD, DSc. PharmInVivo is a spin-out based in the Department of Pharmacology and Pharmacotherapy at the Medical Faculty & Szentagothai Research Center of the University of Pécs. She has worked in the fields of pain and inflammation for decades and has great expertise in a variety of experimental models with special emphasis on in vivo studies.
Impact This is a new multi-disciplinary collaboration that has submitted a grant application to the Wellcome Trust, which was not funded. Discussions within this consortium helped Poyner and Reynolds to submit a successful grant on CGRP.
Start Year 2013
 
Description CGRP antagonists 
Organisation King's College London
Country United Kingdom 
Sector Academic/University 
PI Contribution Modelling interactions of ligands with the CGRP receptor and other proteins.
Collaborator Contribution Pharmonovo supply ligands and coordinate the project David Kendall, PhD, Professor of Pharmacology, University of Nottingham; in vitro investigations of receptor activity and behavioural evaluation of novel compounds in animal models. Over 30 years of experience of GPCR pharmacology. OnTarget Chemistry. Fredrik Lehmann: synthetic chemistry University of Reading. Graeme Cottrell, PhD, Lecturer in Cellular and Molecular Neuroscience; In vitro investigations of the effects of novel compounds on CGRP trafficking and signalling; Over 10 year experience in GPCR trafficking and signalling University of Aston. David Poyner, PhD, Professor of Pharmacology. Mapping antagonist binding sites on the CGRP receptor. 25 year experience of studying the CGRP receptor. University of Essex, Mike Hough, X-ray crystallography Kings College, London. Susan Brain, PhD, Professor of Pharmacology, Vascular Biology and Inflammation. In vivo measurements of blood flow in murine models, especially in first pre-clinical experiments to determine potency, mode of administration and duration of action. PharmInVivo. Zsuzsanna Helyes, MD, PhD, DSc. PharmInVivo is a spin-out based in the Department of Pharmacology and Pharmacotherapy at the Medical Faculty & Szentagothai Research Center of the University of Pécs. She has worked in the fields of pain and inflammation for decades and has great expertise in a variety of experimental models with special emphasis on in vivo studies.
Impact This is a new multi-disciplinary collaboration that has submitted a grant application to the Wellcome Trust, which was not funded. Discussions within this consortium helped Poyner and Reynolds to submit a successful grant on CGRP.
Start Year 2013
 
Description CGRP antagonists 
Organisation OnTarget Chemistry
Country Sweden 
Sector Academic/University 
PI Contribution Modelling interactions of ligands with the CGRP receptor and other proteins.
Collaborator Contribution Pharmonovo supply ligands and coordinate the project David Kendall, PhD, Professor of Pharmacology, University of Nottingham; in vitro investigations of receptor activity and behavioural evaluation of novel compounds in animal models. Over 30 years of experience of GPCR pharmacology. OnTarget Chemistry. Fredrik Lehmann: synthetic chemistry University of Reading. Graeme Cottrell, PhD, Lecturer in Cellular and Molecular Neuroscience; In vitro investigations of the effects of novel compounds on CGRP trafficking and signalling; Over 10 year experience in GPCR trafficking and signalling University of Aston. David Poyner, PhD, Professor of Pharmacology. Mapping antagonist binding sites on the CGRP receptor. 25 year experience of studying the CGRP receptor. University of Essex, Mike Hough, X-ray crystallography Kings College, London. Susan Brain, PhD, Professor of Pharmacology, Vascular Biology and Inflammation. In vivo measurements of blood flow in murine models, especially in first pre-clinical experiments to determine potency, mode of administration and duration of action. PharmInVivo. Zsuzsanna Helyes, MD, PhD, DSc. PharmInVivo is a spin-out based in the Department of Pharmacology and Pharmacotherapy at the Medical Faculty & Szentagothai Research Center of the University of Pécs. She has worked in the fields of pain and inflammation for decades and has great expertise in a variety of experimental models with special emphasis on in vivo studies.
Impact This is a new multi-disciplinary collaboration that has submitted a grant application to the Wellcome Trust, which was not funded. Discussions within this consortium helped Poyner and Reynolds to submit a successful grant on CGRP.
Start Year 2013
 
Description CGRP antagonists 
Organisation Pharmnovo AB/Pharmnovo UK Ltd
Country Sweden 
Sector Private 
PI Contribution Modelling interactions of ligands with the CGRP receptor and other proteins.
Collaborator Contribution Pharmonovo supply ligands and coordinate the project David Kendall, PhD, Professor of Pharmacology, University of Nottingham; in vitro investigations of receptor activity and behavioural evaluation of novel compounds in animal models. Over 30 years of experience of GPCR pharmacology. OnTarget Chemistry. Fredrik Lehmann: synthetic chemistry University of Reading. Graeme Cottrell, PhD, Lecturer in Cellular and Molecular Neuroscience; In vitro investigations of the effects of novel compounds on CGRP trafficking and signalling; Over 10 year experience in GPCR trafficking and signalling University of Aston. David Poyner, PhD, Professor of Pharmacology. Mapping antagonist binding sites on the CGRP receptor. 25 year experience of studying the CGRP receptor. University of Essex, Mike Hough, X-ray crystallography Kings College, London. Susan Brain, PhD, Professor of Pharmacology, Vascular Biology and Inflammation. In vivo measurements of blood flow in murine models, especially in first pre-clinical experiments to determine potency, mode of administration and duration of action. PharmInVivo. Zsuzsanna Helyes, MD, PhD, DSc. PharmInVivo is a spin-out based in the Department of Pharmacology and Pharmacotherapy at the Medical Faculty & Szentagothai Research Center of the University of Pécs. She has worked in the fields of pain and inflammation for decades and has great expertise in a variety of experimental models with special emphasis on in vivo studies.
Impact This is a new multi-disciplinary collaboration that has submitted a grant application to the Wellcome Trust, which was not funded. Discussions within this consortium helped Poyner and Reynolds to submit a successful grant on CGRP.
Start Year 2013
 
Description CGRP antagonists 
Organisation University of Nottingham
Department School of Biomedical Sciences Nottingham
Country United Kingdom 
Sector Academic/University 
PI Contribution Modelling interactions of ligands with the CGRP receptor and other proteins.
Collaborator Contribution Pharmonovo supply ligands and coordinate the project David Kendall, PhD, Professor of Pharmacology, University of Nottingham; in vitro investigations of receptor activity and behavioural evaluation of novel compounds in animal models. Over 30 years of experience of GPCR pharmacology. OnTarget Chemistry. Fredrik Lehmann: synthetic chemistry University of Reading. Graeme Cottrell, PhD, Lecturer in Cellular and Molecular Neuroscience; In vitro investigations of the effects of novel compounds on CGRP trafficking and signalling; Over 10 year experience in GPCR trafficking and signalling University of Aston. David Poyner, PhD, Professor of Pharmacology. Mapping antagonist binding sites on the CGRP receptor. 25 year experience of studying the CGRP receptor. University of Essex, Mike Hough, X-ray crystallography Kings College, London. Susan Brain, PhD, Professor of Pharmacology, Vascular Biology and Inflammation. In vivo measurements of blood flow in murine models, especially in first pre-clinical experiments to determine potency, mode of administration and duration of action. PharmInVivo. Zsuzsanna Helyes, MD, PhD, DSc. PharmInVivo is a spin-out based in the Department of Pharmacology and Pharmacotherapy at the Medical Faculty & Szentagothai Research Center of the University of Pécs. She has worked in the fields of pain and inflammation for decades and has great expertise in a variety of experimental models with special emphasis on in vivo studies.
Impact This is a new multi-disciplinary collaboration that has submitted a grant application to the Wellcome Trust, which was not funded. Discussions within this consortium helped Poyner and Reynolds to submit a successful grant on CGRP.
Start Year 2013
 
Description CGRP antagonists 
Organisation University of Pecs
Department Department of Pharmacology and Pharmacotherapy
Country Hungary 
Sector Academic/University 
PI Contribution Modelling interactions of ligands with the CGRP receptor and other proteins.
Collaborator Contribution Pharmonovo supply ligands and coordinate the project David Kendall, PhD, Professor of Pharmacology, University of Nottingham; in vitro investigations of receptor activity and behavioural evaluation of novel compounds in animal models. Over 30 years of experience of GPCR pharmacology. OnTarget Chemistry. Fredrik Lehmann: synthetic chemistry University of Reading. Graeme Cottrell, PhD, Lecturer in Cellular and Molecular Neuroscience; In vitro investigations of the effects of novel compounds on CGRP trafficking and signalling; Over 10 year experience in GPCR trafficking and signalling University of Aston. David Poyner, PhD, Professor of Pharmacology. Mapping antagonist binding sites on the CGRP receptor. 25 year experience of studying the CGRP receptor. University of Essex, Mike Hough, X-ray crystallography Kings College, London. Susan Brain, PhD, Professor of Pharmacology, Vascular Biology and Inflammation. In vivo measurements of blood flow in murine models, especially in first pre-clinical experiments to determine potency, mode of administration and duration of action. PharmInVivo. Zsuzsanna Helyes, MD, PhD, DSc. PharmInVivo is a spin-out based in the Department of Pharmacology and Pharmacotherapy at the Medical Faculty & Szentagothai Research Center of the University of Pécs. She has worked in the fields of pain and inflammation for decades and has great expertise in a variety of experimental models with special emphasis on in vivo studies.
Impact This is a new multi-disciplinary collaboration that has submitted a grant application to the Wellcome Trust, which was not funded. Discussions within this consortium helped Poyner and Reynolds to submit a successful grant on CGRP.
Start Year 2013
 
Description CGRP antagonists 
Organisation University of Reading
Department School of Pharmacy Reading
Country United Kingdom 
Sector Academic/University 
PI Contribution Modelling interactions of ligands with the CGRP receptor and other proteins.
Collaborator Contribution Pharmonovo supply ligands and coordinate the project David Kendall, PhD, Professor of Pharmacology, University of Nottingham; in vitro investigations of receptor activity and behavioural evaluation of novel compounds in animal models. Over 30 years of experience of GPCR pharmacology. OnTarget Chemistry. Fredrik Lehmann: synthetic chemistry University of Reading. Graeme Cottrell, PhD, Lecturer in Cellular and Molecular Neuroscience; In vitro investigations of the effects of novel compounds on CGRP trafficking and signalling; Over 10 year experience in GPCR trafficking and signalling University of Aston. David Poyner, PhD, Professor of Pharmacology. Mapping antagonist binding sites on the CGRP receptor. 25 year experience of studying the CGRP receptor. University of Essex, Mike Hough, X-ray crystallography Kings College, London. Susan Brain, PhD, Professor of Pharmacology, Vascular Biology and Inflammation. In vivo measurements of blood flow in murine models, especially in first pre-clinical experiments to determine potency, mode of administration and duration of action. PharmInVivo. Zsuzsanna Helyes, MD, PhD, DSc. PharmInVivo is a spin-out based in the Department of Pharmacology and Pharmacotherapy at the Medical Faculty & Szentagothai Research Center of the University of Pécs. She has worked in the fields of pain and inflammation for decades and has great expertise in a variety of experimental models with special emphasis on in vivo studies.
Impact This is a new multi-disciplinary collaboration that has submitted a grant application to the Wellcome Trust, which was not funded. Discussions within this consortium helped Poyner and Reynolds to submit a successful grant on CGRP.
Start Year 2013
 
Description Glucagon and GLP-1 receptor 
Organisation Aston University
Country United Kingdom 
Sector Academic/University 
PI Contribution Molecular modelling: interactions between peptide ligand and receptor
Collaborator Contribution Yeast Cell Biology (Ladds, Warwick until mid 2015; now Cambridge); Pharmacology (Poyner, Aston)
Impact multi-disciplinary: (i) cell biology (Warwick), (ii) pharmacology (Aston), (iii) computational chemistry (comparative modelling, docking, Essex) Publication in preparation, entitled 'Modulation of glucagon receptor pharmacology by RAMP2', by Weston, C., Lu, J., Richards, G. O., Roberts, D. J., Skerry, T. M., Dowell, S. J., Willars, G. B., Reynolds C.A. and Ladds, G. Grant Application on biased signalling in the GLP-1 receptor in preparation (with G. Ladds, D.R. Poyner).
Start Year 2014
 
Description Glucagon and GLP-1 receptor 
Organisation University of Cambridge
Department Department of Pharmacology
Country United Kingdom 
Sector Academic/University 
PI Contribution Molecular modelling: interactions between peptide ligand and receptor
Collaborator Contribution Yeast Cell Biology (Ladds, Warwick until mid 2015; now Cambridge); Pharmacology (Poyner, Aston)
Impact multi-disciplinary: (i) cell biology (Warwick), (ii) pharmacology (Aston), (iii) computational chemistry (comparative modelling, docking, Essex) Publication in preparation, entitled 'Modulation of glucagon receptor pharmacology by RAMP2', by Weston, C., Lu, J., Richards, G. O., Roberts, D. J., Skerry, T. M., Dowell, S. J., Willars, G. B., Reynolds C.A. and Ladds, G. Grant Application on biased signalling in the GLP-1 receptor in preparation (with G. Ladds, D.R. Poyner).
Start Year 2014
 
Description Glucagon and GLP-1 receptor 
Organisation University of Warwick
Department Warwick Medical School
Country United Kingdom 
Sector Academic/University 
PI Contribution Molecular modelling: interactions between peptide ligand and receptor
Collaborator Contribution Yeast Cell Biology (Ladds, Warwick until mid 2015; now Cambridge); Pharmacology (Poyner, Aston)
Impact multi-disciplinary: (i) cell biology (Warwick), (ii) pharmacology (Aston), (iii) computational chemistry (comparative modelling, docking, Essex) Publication in preparation, entitled 'Modulation of glucagon receptor pharmacology by RAMP2', by Weston, C., Lu, J., Richards, G. O., Roberts, D. J., Skerry, T. M., Dowell, S. J., Willars, G. B., Reynolds C.A. and Ladds, G. Grant Application on biased signalling in the GLP-1 receptor in preparation (with G. Ladds, D.R. Poyner).
Start Year 2014
 
Description Industry Interchange 
Organisation GlaxoSmithKline (GSK)
Department Discovery Partnerships with Academia
Country Global 
Sector Private 
PI Contribution Novel QM/MM methods that include a polarizable MM region for application to fragment-based drug design (FBDD)
Collaborator Contribution Advice in how to apply these methods to FBDD
Impact See publications involving Ian Wall
Start Year 2010
 
Description Modelling polarization 
Organisation University of South Bohemia
Country Czech Republic 
Sector Academic/University 
PI Contribution Intellectual input, computing resources and programming skills
Collaborator Contribution Intellectual input, computing resources and programming skills, with an emphasis on quantum chemistry and programing.
Impact Polarized docking software
Start Year 2011
 
Title polarization software 
Description The search for a new drug may start on the computer by 'docking' potential molecules into a structure of the drug target, which is typically an enzyme or a receptor. Molecules that are calculated to fit well can therefore be made and tested experimentally, while those calculated to have a poor fit can be ignored, thus saving time and expense. However, these calculations do not always work well. These calculations usually assumes that the atomic charge distribution on the molecule and the enzyme does not change when the molecule approaches the enzyme even when the charges on some of the atoms are quite high and might therefore affect each other, i.e. one molecule might polarize the other. We have developed a method of including enzyme polarization and ligand polarization in docking that can be combined with standard state-of-the art docking software, e.g. Glide. This should greatly reduce one of the main errors in docking. The method is based on a series of Perl scripts and converts an induced dipole to a set of induced charges. The induced dipole can be calculated classically, or quantum mechanically. Typically the induced dpole at the enzyme is calculated from the ligand quantum mechanical electrostatic potential at the atoms of the enzyme. 
Type Of Technology Software 
Year Produced 2011 
Open Source License? Yes  
Impact Inclusion of polarization by this method typically halves the proportion of compounds incorrectly docked using GLIDE, a state-of the art docking program and therefore has the potential to facilitate the drug design process. This is particularly true when appropriate water molecules are included as part of the enzyme target. 
URL http://ftp://ftp.essex.ac.uk/pub/oyster/polarization
 
Description Drug Design Workshop for the giften and able 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Schools
Results and Impact 8 Gifted and able students from Bromfords School, Essex, attended a week-long drug design workshop, which greatly increased the pupils enthusiasm for science.
Year(s) Of Engagement Activity 2016